Abstract
Objective. The aim of this retrospective study was to evaluate the prognostic factors for long-term survival (> 5 years) in patients with stage IV NSCLC. Methods. We reviewed 66 patients with stage IV NSCLC who were diagnosed at our hospital from 10/1/2002 to 9/30/2010. Results. In comparison to 58 patients who survived for < 5 years, 8 patients who survived for > 5 years were more likely to have an EGFR mutation positive, an early N status (N0, N1), and a single metastatic site. Age < 75 years, an early N status (N0, N1), and the absence of liver metastasis were independent prognostic factors. Among the patients who survived for >5 years, the rate of EGFR-TKI use was higher, the rate of disease control in patients who were treated with both cytotoxic drugs and an EGFR-TKI was higher, and progression-free survival was longer in patients who were treated with cytotoxic drugs and an EGFR-TKI in comparison to patients who survived for < 5 years. Conclusion. Our results suggest that age <75 years, an early N status (N0, N1), and the absence of liver metastasis may contribute to long-term survival in patients with stage IV NSCLC. We should take these results into consideration when deciding aggressive therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 88-95 |
| Number of pages | 8 |
| Journal | Japanese Journal of Lung Cancer |
| Volume | 57 |
| Issue number | 2 |
| Publication status | Published - 2017 Apr 20 |
| Externally published | Yes |
Fingerprint
Keywords
- Long-term survivor
- Non-small cell lung cancer (NSCLC
- Stage IV
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
Cite this
The prognostic factors for long-term (≥5 Years) survival in stage IV Non-small cell lung cancer. / Matsuzaki, Tatsu; Ikemura, Shinnosuke; Chubachi, Shotaro; Nakayama, Shingo; Iwami, Eri; Sato, Minako; Nakajima, Takahiro; Eguchi, Keisuke; Terashima, Takeshi.
In: Japanese Journal of Lung Cancer, Vol. 57, No. 2, 20.04.2017, p. 88-95.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The prognostic factors for long-term (≥5 Years) survival in stage IV Non-small cell lung cancer
AU - Matsuzaki, Tatsu
AU - Ikemura, Shinnosuke
AU - Chubachi, Shotaro
AU - Nakayama, Shingo
AU - Iwami, Eri
AU - Sato, Minako
AU - Nakajima, Takahiro
AU - Eguchi, Keisuke
AU - Terashima, Takeshi
PY - 2017/4/20
Y1 - 2017/4/20
N2 - Objective. The aim of this retrospective study was to evaluate the prognostic factors for long-term survival (> 5 years) in patients with stage IV NSCLC. Methods. We reviewed 66 patients with stage IV NSCLC who were diagnosed at our hospital from 10/1/2002 to 9/30/2010. Results. In comparison to 58 patients who survived for < 5 years, 8 patients who survived for > 5 years were more likely to have an EGFR mutation positive, an early N status (N0, N1), and a single metastatic site. Age < 75 years, an early N status (N0, N1), and the absence of liver metastasis were independent prognostic factors. Among the patients who survived for >5 years, the rate of EGFR-TKI use was higher, the rate of disease control in patients who were treated with both cytotoxic drugs and an EGFR-TKI was higher, and progression-free survival was longer in patients who were treated with cytotoxic drugs and an EGFR-TKI in comparison to patients who survived for < 5 years. Conclusion. Our results suggest that age <75 years, an early N status (N0, N1), and the absence of liver metastasis may contribute to long-term survival in patients with stage IV NSCLC. We should take these results into consideration when deciding aggressive therapy.
AB - Objective. The aim of this retrospective study was to evaluate the prognostic factors for long-term survival (> 5 years) in patients with stage IV NSCLC. Methods. We reviewed 66 patients with stage IV NSCLC who were diagnosed at our hospital from 10/1/2002 to 9/30/2010. Results. In comparison to 58 patients who survived for < 5 years, 8 patients who survived for > 5 years were more likely to have an EGFR mutation positive, an early N status (N0, N1), and a single metastatic site. Age < 75 years, an early N status (N0, N1), and the absence of liver metastasis were independent prognostic factors. Among the patients who survived for >5 years, the rate of EGFR-TKI use was higher, the rate of disease control in patients who were treated with both cytotoxic drugs and an EGFR-TKI was higher, and progression-free survival was longer in patients who were treated with cytotoxic drugs and an EGFR-TKI in comparison to patients who survived for < 5 years. Conclusion. Our results suggest that age <75 years, an early N status (N0, N1), and the absence of liver metastasis may contribute to long-term survival in patients with stage IV NSCLC. We should take these results into consideration when deciding aggressive therapy.
KW - Long-term survivor
KW - Non-small cell lung cancer (NSCLC
KW - Stage IV
UR - http://www.scopus.com/inward/record.url?scp=85019547512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019547512&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85019547512
VL - 57
SP - 88
EP - 95
JO - Japanese Journal of Lung Cancer
JF - Japanese Journal of Lung Cancer
SN - 0386-9628
IS - 2
ER -